The purpose of the study is to find out how many patients with coronary artery disease and prediabetes can return to normal blood sugar levels when treated with these blood sugar-lowering medications. The study will also look at whether patients with prediabetes have more problems with their eyes, kidneys, nerves, and liver compared to patients with normal blood sugar levels. During the study, patients will receive treatment for one year, and then they will be followed for another year to see if their blood sugar levels stay normal or if prediabetes comes back, or if they develop diabetes.

The study will measure blood sugar control using a blood test called HbA1c, which shows the average blood sugar level over the past few months. Other measurements will include kidney function tests, liver health markers, cholesterol levels, body weight, and waist size. The study will also check for complications that can affect the eyes, kidneys, and nerves, as well as a liver condition called MASLD, which is a buildup of fat in the liver. The study will compare patients who receive the blood sugar-lowering medications with those who receive standard care to see which approach is more effective in bringing blood sugar levels back to normal and preventing diabetes.

The study aims to determine if CIR-NA can help people with prediabetes achieve remission, which means returning their blood sugar levels to normal. The study will compare CIR-NA against placebo over a period of 26 weeks. During this time, researchers will monitor various aspects of blood sugar control, including fasting plasma glucose, glycated hemoglobin, and glucose tolerance.

Participants will receive either CIR-NA tablets or placebo tablets. The maximum daily dose of CIR-NA will be 200 mg, and the treatment will continue for approximately 6 months. The study will measure how well the medication works by checking if participants’ prediabetes improves and whether it prevents progression to type 2 diabetes mellitus.

The main purpose is to find out which treatment approach works best in reducing liver fat over an 18-month period. The amount of fat in the liver will be measured using Magnetic Resonance Imaging (MRI), which is a scanning technique that creates detailed pictures of the inside of the body without using radiation.

During the study, participants will receive different combinations of these medications along with lifestyle recommendations. The study will also look at how the body processes insulin, examine various substances in the blood, study gut bacteria, and look at how genetic differences might affect how well the treatments work. The total duration of treatment is 18 months, during which participants will take either Pioglitazone (15 mg daily) or Metformin (up to 1000 mg daily), or both medications together.

Participants in the study will receive their assigned treatment through an intravenous infusion, which means the medication is delivered directly into the bloodstream. The study will last for a period of four weeks, during which the participants will be closely monitored. The goal is to see how long it takes for the participants to develop symptoms of Type 1 Diabetes and to observe any side effects that may occur from the treatments. The study will also track the participants’ health over a longer period to gather more information about the treatments’ long-term effects.

This trial is important for understanding how to prevent or delay the onset of **Type 1 Diabetes** in children who are at risk. By comparing different treatment options, researchers hope to find the most effective way to manage the disease before it fully develops. The study will provide valuable insights into the potential benefits and risks of using **Tregs** and **Rituximab** in treating early-stage **Type 1 Diabetes**.

The purpose of the study is to compare the effectiveness of these medications in slowing down or reversing the buildup of plaque in the arteries of the heart, which is a key factor in coronary artery disease. The study will last for 24 months, during which participants will receive one of the medications along with advice on diet and lifestyle changes. The progress of the disease will be monitored using a special type of X-ray called computed tomography (CT), which provides detailed images of the heart and its blood vessels.

Participants will be randomly assigned to receive either semaglutide, dapagliflozin, metformin, or a placebo. The study aims to observe how these treatments affect the progression of coronary artery disease and other health factors such as weight, blood pressure, and cholesterol levels. The results will help determine which medication is most effective in managing coronary artery disease in patients with prediabetes.

The purpose of the study is to compare the development of type 2 diabetes over a period of 160 weeks between those receiving semaglutide and those receiving the placebo. The study will monitor participants’ blood sugar levels using tests such as fasting glycaemia, oral glucose tolerance test (OGTT), and HbA1c, which is a measure of average blood sugar levels over the past three months. These tests will help determine if semaglutide can effectively prevent the progression to type 2 diabetes in women with a history of gestational diabetes and current glucose intolerance.

Throughout the study, participants will be regularly assessed to track their health and any changes in their condition. The study will also look at secondary outcomes, such as the need for additional diabetes treatment, changes in body weight, and improvements in blood sugar control. The trial aims to provide valuable insights into the potential benefits of semaglutide for preventing type 2 diabetes in this specific group of women.